+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028

  • ID: 5306331
  • Report
  • March 2021
  • Region: Global
  • 555 Pages
  • Kuick Research
UP TO OFF
until Apr 30th 2021
1 of 4

FEATURED COMPANIES

  • Ablynx
  • Amgen
  • Eli Lilly
  • Genentech
  • Jounce Therapeutics
  • Neovii Biotech
  • MORE

Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028 Report Highlights:

  • Global Bispecific Antibody Market Opportunity: > US$ 18 Billion 
  • Global Bispecific Antibody Market Growth Rate: 121% CAGR (2016 -2020)
  • Global Bispecific Antibody Sales In 2020: >55%
  • Bispecific Antibodies In Clinical Trials: More Than 400 Antibodies
  • Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
  • Approved Bispecific Antibodies Dosage, Patent, Price, Yearly Sales, Quarterly Sales, Global and Regional Sales Insight

The unique achievements gathered through monoclonal antibody market led to the identification of novel wave of antibody market classified as Bispecific cancer antibody market. In a very imperative and innovative way, bispecific cancer antibody market applications have prompted the oncology researchers to multiply the healthcare benefits received by the patients suffering from different types of cancers. The whole procedure followed by the drugs available under the market involves targeting two specific molecules present on the surface of cancer antigens. The same has been verified in several different pre-clinical and clinical settings, thus anticipating the therapy market to deliver promising healthcare outcomes to the patients who have developed resistance to other available therapies. 

Currently 2 Bispecific Antibodies Blincyto And Hemlibra Are Commercially Available In Market, Hemlibra Accounts For More Than 85% Of Global Bispecific Antibody Market

In the past few years, global bispecific cancer antibody market has cleared its clinical evaluation for different types of cancers which involves: cancer at early stage, last stage and solid cancers. More precisely, the therapy at an international level is getting leveraged due to its uniqueness and imperative approach of targeting molecules which are highly differentiated in all sub-types of cancers. Despite of introducing monoclonal antibody therapy in the cancer therapeutics several decades ago, researchers got to acknowledge the applications of adding the capability of an antibody to act on two targets few years ago. It is predicted that advancement in pharmaceutical market technology, thanks to science and medical progress, the therapy is leading the entire cancer therapeutics market towards a novel era of progress and scientific achievements. 

Since First Approved and Launched Bispecific Antibody In 2015, The Global Bispecific Antibody Market Has Witnessed Growth of 121% CAGR Till 2020

In addition, the constantly increasingly knowledge with respect to the surface antigens present on the cancer cells as well as several different tools through which a probe could be generated against the sequence of antigen is also believed to boost the researchers to cope-up with the complex challenges observed in the cancer therapeutics market by the applications of bispecific cancer antibodies. It is further believed to develop a massive competitive landscape threat to all the other viable and commercially available cancer therapies such as old and traditional chemotherapy or radiation therapy and novel therapies such as small molecule cancer drug therapy. 

As per Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028 report findings, it is predicted that in the next few successful years of clinical research studies associated with the therapy, it will lead to completely revolutionize the entire cancer treatment regimen and the overall future direction of cancer therapeutics. By growing at an accelerated speed in small period of time, the therapy market has also remained successful in getting represented as one of the most exciting approach in the entire biotech space and sector. Increase in the volume of recent publications, articles and research papers with respect to the therapy applications by manipulating it at molecular level by the available tools are also estimated to expand the market parameters. In addition, the unprecedented market drivers associated with the therapy are also believed to be digging deep to increase the performance rate of the therapy. To conclude, it can be stated that the overall therapy market achievements are commitment to cause a total advancement in the global cancer therapeutics market by acting broad spectrally. 

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ablynx
  • Amgen
  • Eli Lilly
  • Genentech
  • Jounce Therapeutics
  • Neovii Biotech
  • MORE

1. Introduction to Bispecific Monoclonal Antibody

2. Advantage of Bispecific Antibodies Over Monospecific Monoclonal Antibodies

3. Bispecific Antibodies - Development Process & Mechanism of Action
3.1 Development  of Bispecific Antibodies Similar to IgG
3.2 Development  of Small Bispecific Antibodies
3.3 General Mechanism of Bispecific Antibodies

4. Approved Bispecific Antibodies Mechanism of Action
4.1 Hemlibra
4.2 Blincyto

5. Application of Bispecific Antibodies in Cancer
5.1 Cancer Diagnosis
5.2 Cancer Targeting By Blocking Signaling Pathways
5.3 Targeting Tumor Angiogenesis for Cancer Treatment

6. Miscellaneous Application of Bispecific Antibodies
6.1 Diagnosis of Microbial Infectious Diseases
6.2 Specific Delivery of Effector Compounds to Targets
6.3 Bispecific Antibodies as Genetic Antibody Therapy

7. Global & Regional Bispecific Antibody Market Outlook
7.1 Yearly & Quarterly Indicators
7.2 Approved Bispecific Antibodies Reimbursement Policy
7.3 Blincyto Reimbursement Policy
7.4 Hemlibra Reimbursement Policy

8. Blincyto: First Approved Bispecific Antibody 2015
8.1 Dosage & Price Analysis
8.2 Global & Regional Sales Analysis

9. Hemlibra: Second Approved Bispecific Antibody 2018
9.1 Dosage & Price Analysis
9.2 Global & Regional Sales Analysis

10. Global Bispecific Antibodies Clinical Pipeline Overview
10.1 By Phase
10.2 By  Country/Region
10.3 By  Company
10.4 By Indication
10.5 Orphan Designated Bispecific Antibodies
10.6 Patient Segment

11. Ongoing Bispecific Antibodies Clinical Trials By Company, Country, Indication & Phase
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-II/III
11.7 Phase-III
11.8 Preregistration

12. Marketed Bispecific Antibodies Clinical Insight
12.1 Blinatumomab - Amgen
12.2 Emicizumab - Chugai Pharmaceutical

13. Global Bispecific Antibody Market Dynamics
13.1 Favorable Market Parameters
13.2 Commercialization Challenges

14. Global Bispecific Antibody Market Future Prospects

15. Competitive Landscape
15.1 Ablynx
15.2 Adimab
15.3 Affimed Therapeutics
15.4 Amgen
15.5 AstraZeneca (MedImmune)
15.6 Chugai Pharmaceutical
15.7 Eli Lilly
15.8 EMD Serono
15.9 Emergent BioSolutions
15.10 Genentech
15.11 Genmab
15.12 Immunomedics
15.13 Jounce Therapeutics
15.14 MacroGenics
15.15 Merus
15.16 Neovii Biotech
15.17 NovImmune SA
15.18 OncoMed Pharmaceuticals
15.19 Pieris
15.20 Regeneron Pharmaceuticals
15.21 Roche
15.22 Sanofi

List of Figures
Figure 2-1: Advantages of Bispecific Antibodies
Figure 3-1: Types of Approaches to Form IgG like Bispecific Antibodies
Figure 3-2: Method of Formation of Hybrid Hybridoma
Figure 3-3: Limitations of Hybrid Hybridoma
Figure 3-4: Steps involved in “Knobs into Holes” Approach
Figure 3-5: Three different CrossMabs are Obtained by Three Different Modifications
Figure 3-6: Method for formation of Dual-Variable-Domain Immunoglobulin
Figure 3-7: Advantages of Dual Variable Domain Immunoglobulin approach
Figure 3-8: Types of Bispecific Antibodies
Figure 3-9: Bispecific Antibodies - General Mechanism of Action
Figure 3-10: Bispecific Antibodies: Pathways for Induction of Cytotoxicity
Figure 4-1: Hemlibra - Mechanism of Action
Figure 4-2: Blincyto - Mechanism of Action
Figure 5-1: Application of Bispecific Antibodies in Cancer
Figure 7-1: Global - Bispecific Antibody Market Size (US$ Million), 2016 - 2020
Figure 7-2: US - Bispecific Antibody Market Size (US$ Million), 2016 - 2020
Figure 7-3: Global (Ex USA) - Bispecific Antibody Market Size (US$ Million), 2016 - 2020
Figure 7-4: US v/s ROW - Bispecific Antibody Market Share (%), 2020
Figure 7-5: US v/s ROW - Bispecific Antibody Market Share (%), 2019
Figure 7-6: US v/s ROW - Bispecific Antibody Market Share (%), 2018
Figure 7-7: Global - Bispecific Antibody Market Size (US$ Million) by Products (Blincyto & Hemlibra), 2018 - 2020
Figure 7-8: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra), 2020
Figure 7-9: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra), 2019
Figure 7-10: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra), 2018
Figure 7-11: Global - Bispecific Antibody Quarterly Sales (US$ Million), by Products (Blincyto & Hemlibra), 2019
Figure 7-12: Blincyto - Total Treatment Cost & Reimbursement Cost
Figure 7-13: Blincyto - In Pocket & Out of Pocket Cost of Treatment
Figure 7-14: Hemlibra - Total Treatment Cost & Reimbursement Cost
Figure 7-15: Hemlibra - In Pocket & Out of Pocket Cost of Treatment
Figure 8-1: Blincyto - Recommended Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, December’2019
Figure 8-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days), December’2019
Figure 8-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-Cell Precursor ALL (US$), December’2019
Figure 8-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, December’2019
Figure 8-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), December’2019
Figure 8-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), December’2019
Figure 8-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), December’2019
Figure 8-8: Blincyto - Sales Value (US$ Million), 2015 - 2020
Figure 8-9: US - Blincyto Sales Value (US$ Million), 2016 - 2020
Figure 8-10: Global ( Ex USA) - Blincyto Sales Value (US$ Million), 2016 - 2020
Figure 8-11: Global - Quarterly Sales Value (US$ Millions), 2020
Figure 8-12: Blincyto - Quarterly Sales Value (US$ Million), 2019
Figure 8-13: Blincyto - Quarterly Sales Value (US$ Million), 2018
Figure 8-14: Blincyto - US v/s Rest of World Share in Sales Value (%), 2020
Figure 8-15: Blincyto - US v/s Rest of World Share in Sales Value (%), 2019
Figure 8-16: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
Figure 9-1: Hemlibra - Cost for Single Unit of 30mcg & 150mcg Subcutaneous Injection (US$), December’2019
Figure 9-2: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/Kg/Week), December’2019
Figure 9-3: Hemlibra - Average Monthly & Annual Cost for Treatment of Hemophilia A (US$), December’2019
Figure 9-4: Global - Hemlibra Sales Value (US$ Million), 2018 - 2020
Figure 9-5: US- Hemlibra Sales Value (US$ Million), 2018 - 2020
Figure 9-6: Europe- Hemlibra Sales Value (US$ Million), 2018- 2020
Figure 9-7: Japan- Hemlibra Sales Value (US$ Million), 2018 - 2020
Figure 9-8: Hemlibra - Sales Value by Countries (US$ Million), 2020
Figure 9-9: Hemlibra - Sales Growth by Countries (%), 2020
Figure 9-10: Hemlibra - Sales Growth by Countries (US$ Million), 2019
Figure 9-11: Hemlibra - Sales Value by Countries (US$ Million), 2018
Figure 9-12: Hemlibra - Sales Value Share by Countries (%), 2020
Figure 9-13: Hemlibra - Sales Value Share by Countries (%), 2019
Figure 9-14: Hemlibra - Sales Value Share by Countries (%), 2018
Figure 9-15: Global - Hemlibra Quarterly Sales Value (US$ Million), 2018
Figure 9-16: Global - Hemlibra Half Yearly Sales Value (US$ Million), 2018 & 2019
Figure 9-17: Hemlibra - Half Year Sales Value by Countries (US$ Million), 2018 & 2019
Figure 9-18: Hemlibra - Quarterly Sales Value (US$ Million), 2019
Figure 9-19: Hemlibra - 9 Months Sales Value by Countries (US$ Million), 2019
Figure 9-20: Hemlibra - 9 Month Sales Value Share by countries (%), 2019
Figure 10-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (%), 2021 till 2028
Figure 10-2: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2021 till 2028
Figure 10-3: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2021 till 2028
Figure 10-4: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2021 till 2028
Figure 10-5: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2021 till 2028
Figure 10-6: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2021 till 2028
Figure 10-7: Global - Bispecific Antibodies in Clinical Pipeline by Patient Segment (Numbers), 2021 till 2028
Figure 13-1: Favorable Market Parameters Global Bispecific Antibody Market
Figure 13-2: Commercialization Challenges for Bispecific Antibody
Figure 14-1: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2021 - 2028
Figure 15-1: Ablynx - Clinical Pipeline
Figure 15-2: Affimed Therapeutics - Clinical Pipeline
Figure 15-3: Amgen - Clinical Pipeline
Figure 15-4: EMD Serono - Clinical Pipeline
Figure 15-5: Emergent Bioscience - Clinical Pipeline
Figure 15-6: Genmab - Clinical Pipeline
Figure 15-7: Jounce Therapeutics - Clinical Pipeline
Figure 15-8: MacroGenics - Clinical Pipeline
Figure 15-9: Merus - Clinical Pipeline
Figure 15-10: Novimmune - Clinical Pipeline
Figure 15-11: OncoMed - Clinical Pipeline
Figure 15-12: Pieris Pharmaceuticals - Clinical Pipeline
Figure 15-13: Roche - Clinical Pipeline

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ablynx
  • Adimab
  • Affimed Therapeutics
  • Amgen
  • AstraZeneca (MedImmune)
  • Chugai Pharmaceutical
  • Eli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Genentech
  • Genmab
  • Immunomedics
  • Jounce Therapeutics
  • MacroGenics
  • Merus
  • Neovii Biotech
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll